Reneuron Share Discussion Threads

[manc10] 07/4/2020 19:52

anybody seen raytard

[manc10] 07/4/2020 19:52

anybody seen raytard

[manc10] 07/4/2020 19:52

anybody seen raytard

[small crow] 07/4/2020 14:23

People waking up to potential here.

[martinfrench] 07/4/2020 09:04

And depends on reneurons definition of major. For us that would be one of the biggest but not sure that is the case

[martinfrench] 07/4/2020 09:02

Unusual RNs, when does the detail come out ? And was it rushed out for any reason ?

Similar terms to last one, few mill up front to explore and then more down the line if adopted ?

[bonzo] 07/4/2020 08:26

Certainly looks encouraging...

[rayrac] 07/4/2020 07:58

👍🏽

[ayl30] 07/4/2020 07:05

Good rns today, keep them coming

[dickbush] 03/4/2020 10:54

4/Jan/2019
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that it has signed a collaboration agreement with a US-based biopharmaceutical company to explore the use of the Company's exosome technology platform as a potential delivery vehicle for synthetic oligonucleotides used in gene therapy.
In the collaboration, ReNeuron will use its proprietary exosomes as well as sequence-based know-how and the US-based biopharmaceutical company will provide its expertise in the field of synthetic oligonucleotides to optimise their loading into exosomes. If the initial feasibility stage of the collaboration is successful, candidates with suitable pharmaceutical properties will be taken into the next part of the collaboration which will evaluate pre-clinical safety and potential efficacy.
Commenting on the agreement, Olav Hellebø, Chief Executive Officer of ReNeuron, said:
"Exosomes are biological nanoparticles ideally suited to the delivery of nucleic acid-based therapeutics due to their natural occurrence and abundance, their ability to protect their cargo from degradation and their potential for favourable bio-distribution. We are delighted to be collaborating with a biopharmaceutical company that has considerable experience in the development of novel oligonucleotide-based therapeutics."
From Wikipedia
Antisense oligonucleotides are single strands of DNA or RNA that are complementary to a chosen sequence.[4] In the case of antisense RNA they prevent protein translation of certain messenger RNA strands by binding to them, in a process called hybridization.[9] Antisense oligonucleotides can be used to target a specific, complementary (coding or non-coding) RNA. If binding takes place this hybrid can be degraded by the enzyme RNase H.[9] RNases H is an enzyme that hydrolyzes RNA, and when used in an antisense oligonucleotide application results in 80-95% down-regulation of mRNA expression.[4]
The use of morpholino-antisense oligonucleotides for gene knockdowns in vertebrates, which is now a standard technique in developmental biology and is used to study altered gene expression and gene function, was first developed by Janet Heasman using Xenopus. The antisense oligonucleotides have also been used to inhibit influenza virus replication in cell lines.

AND

Nucleic Acid-Mediated Cleavage of M1 Gene of Influenza A Virus Is Significantly Augmented by Antisense Molecules Targeted to Hybridize Close to the Cleavage Site

Influenza A virus genome segment 7 encodes protein M1, which is the matrix protein playing crucial role in the virus life cycle. Any antiviral strategy that aims at reducing, in particular, the expression of this genome segment should, in principle, reduce the infectivity of the virus. We developed a specific antiviral approach at the molecular level and designed several novel 10–23 DNAzymes (Dz) and hammerhead ribozymes (Rz), specifically targeted to cleave at the conserved domains of the influenza virus M1 RNA. We sought to use antisense molecules with the hope that it will facilitate the ribozyme-mediated cleavage. We observed that the Mg2+-dependent sequence-specific cleavage of M1 RNA was achieved by both the Dz and Rz in a dose-dependent manner. This combination of catalytic Dz and Rz with antisense molecules, in principle, resulted in more effective gene suppression, inhibited the whole virus replication in host cell, and thus could be exploited for therapeutic purposes.

[supernumerary] 03/4/2020 10:00

Nice to see a bit of life! RNS doesn't say much, but at least they're making progress, on several fronts, too.

Exosomes are quite a hot area, hence my interest in the Evox deal, so Mr Adams really ought to get his finger out and line up big pharma. And what about Fosun again for China and the Far East?

It would also be good if they were to release the unpublished data in a few weeks, just to keep the newsflow going. Doesn't need to be peer-reviewed, even a White Paper would ensure it got out.

[tell sid] 03/4/2020 08:22

Dipped my toe in yestyerday.

[supernumerary] 30/3/2020 17:12

They started some action with the exosomes back at the beginning of 2019:





but it seems to have gone nowhere. No use having assets sitting on the shelf gathering dust - if they can't be used they should be sold for whatever they can get, with a payback on future royalties.

[dickbush] 30/3/2020 15:24

All the Evox post reminded me was

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces the appointment of Nicholas Adams in the newly created role of VP Business Development & Alliance Management.

That was July 2019.

Where's the beef?

[supernumerary] 28/3/2020 11:21

What was the point of posting that?

[dogwalker] 27/3/2020 21:22

What's the point of posting all that here?

[supernumerary] 27/3/2020 17:26

Deals still being done...



Evox Therapeutics and Takeda Sign Multi-target Rare Disease Collaboration
Collaboration focuses on developing novel protein replacement and mRNA therapies and explores the targeted delivery of these payloads using Evox's proprietary exosome technology

Partnership encompasses up to five rare disease targets, including Evox's Niemann-Pick Type C programme, with Takeda assuming responsibility for its clinical development

OXFORD, England, March 26, 2020 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, is pleased to announce the signing of a rare disease-focused partnership with Takeda Pharmaceutical Company Limited ("Takeda"). The multi-target collaboration is focussed on developing up to five novel protein replacement and mRNA therapies, including Evox's preclinical programme in Niemann-Pick disease type C (NPC) and a second new programme directed at another undisclosed rare disease. As part of the deal, Takeda also has the option to select up to three additional rare disease targets.

Dr. Antonin de Fougerolles, Chief Executive Officer of Evox, commented: "We are delighted to have entered into this strategically important, multi-target partnership with Takeda, a recognised leader in the development of treatments for rare diseases. We look forward to working with Takeda to advance these exosome drugs towards the clinic. Additionally, the deal significantly extends our cash runway into late 2022 and allows us to aggressively expand our own proprietary pipeline of rare disease drugs, including a urea cycle disorder programme we expect to enter the clinic in 2021."

The partnership with Takeda enables Evox to continue advancing its proprietary exosome-based targeting and delivery technology, while also leveraging Takeda's extensive development and clinical expertise to advance these partnered programmes into the clinic.

Madhu Natarajan, Head of the Rare Diseases Drug Discovery Unit at Takeda, commented: "Evox Therapeutics has developed a novel approach toward treating devastating diseases, such as Niemann-Pick Type C. The targeted and non-targeted exosomes offer a highly differentiated platform with the potential to enhance tissue delivery for a variety of payloads like mRNA and proteins. Collaborating on the Evox exosome platform also complements our expanding capabilities in cell and gene therapies, particularly with the potential to develop new delivery approaches in addition to our cutting-edge adeno associated virus platform, to provide transformative therapies or functional cures for people living with rare diseases."

Under the terms of the agreement, Evox will be eligible to receive up to $44 million in upfront, near-term milestone payments and research funding. In total, Evox is eligible to receive approximately $882 million in upfront, development, and commercial milestone payments from Takeda. Evox will also receive tiered royalties on net sales of each product.

Evox will be primarily responsible for research and development activities for each programme until IND-enabling studies and for manufacturing up to and including Phase 1 clinical trials. Takeda will reimburse Evox for manufacturing costs incurred after the pre-clinical handover of the programmes.

About Evox Therapeutics

Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of therapeutics. Backed by leading life sciences venture capital groups and supported by a comprehensive intellectual property portfolio, Evox's mission is to positively impact human health by creating novel exosome-based therapeutics for the treatment of various severe diseases with limited options for patients and their families. Evox has created substantial proprietary technology to modify exosomes using various molecular engineering, drug loading, and targeting strategies to facilitate targeted drug delivery to organs of interest, including the brain and the central nervous system. Exosome-based drugs have the potential to address some of the limitations of protein, antibody and nucleic acid-based therapies by enabling delivery to cells and tissues that are currently out of reach using other drug delivery technologies, and Evox is leading the development within this emerging therapeutic space.

[napoleon 14th] 26/3/2020 03:13

"but do those who live for that have anything else to live for? "

My point exactly...

[dickbush] 25/3/2020 08:35

napoleon, If you read it again, the key words are "take no notice of this". Just follow the advice and then pay no time worrying about what the market or your shares are doing. No need to check your shares' prices. Just get on with your life.